27 August 2026
Elecsys pTau217 blood test cleared for amyloid assessment
On August 24, 2026, the U.S. FDA cleared the Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test from Roche and Eli Lilly and Company for adults 55 and older with signs of cognitive decline.
The full briefing is in the app.